|
1
|
Myonecrosis after revascularization procedures.
|
J Am Coll Cardiol
|
1998
|
2.11
|
|
2
|
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
|
Eur Heart J
|
2004
|
1.59
|
|
3
|
A dose-determining trial of heparinase-I (Neutralase) for heparin neutralization in coronary artery surgery.
|
Anesth Analg
|
2001
|
1.42
|
|
4
|
Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.
|
Ann Thorac Surg
|
2000
|
0.86
|
|
5
|
Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
|
Am J Cardiol
|
2000
|
0.80
|
|
6
|
Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. Importance and implications.
|
JAMA
|
1997
|
0.78
|
|
7
|
Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application.
|
Proc AMIA Annu Fall Symp
|
1997
|
0.75
|
|
8
|
Evaluating the potential 'economic attractiveness' of new therapies in patients with non-ST elevation acute coronary syndrome.
|
Pharmacoeconomics
|
2000
|
0.75
|
|
9
|
Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial.
|
Am J Cardiol
|
2001
|
0.75
|
|
10
|
Use of calcium channel antagonists in myocardial revascularization procedures.
|
Am J Cardiol
|
1996
|
0.75
|